Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-2.44%||68.93||1.0%||$497.91m|
|REGN||Regeneron Pharmaceuticals, Inc.||-2.73%||636.53||2.7%||$490.45m|
|VRTX||Vertex Pharmaceuticals, Inc.||-1.67%||186.94||1.9%||$375.32m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.88%||4.61||0.7%||$322.26m|
|EXAS||EXACT Sciences Corp.||-1.39%||85.37||18.0%||$167.68m|
|BMRN||BioMarin Pharmaceutical, Inc.||-1.27%||86.29||4.2%||$144.64m|
Ocugen, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies to cure eye diseases. Its product pipeline candidates include OCU400, OCU410, OCU200, and COVAXIN. The firm's modifier gene therapy platform is engaged in addressing retinal diseases, including retinitis pigmentosa, leber congenital amaurosis, and dry age-related macular degeneration. The company was founded by Shankar Musunuri and Uday B. Kompella in 2013 and is headquartered in Malvern, PA.